Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.49 |
| ▸ | HTR3B | O95264 | 1/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | NPFFR2 | Q9Y5X5 | 3/20 | 0.43 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1525499 | 0.94 | HTR3E (0.44) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL30019653 | 0.94 | HTR3E (0.44) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL1513809 | 0.93 | HTR3E (0.43) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL27734542 | 0.93 | HTR3E (0.43) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL28217604 | 0.93 | GRM4 (0.44) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL1513968 | 0.90 | NPFFR2 (0.43) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL27702049 | 0.90 | HTR3E (0.41) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL28070235 | 0.88 | HTR3E (0.40) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL27514280 | 0.87 | TRPV1 (0.43) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL17060479 | 0.85 | HTR3E (0.47) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270878-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER HEALTHERCARE LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-7517880-B2 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-20090093526-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER HEALTHCARE LLC | 2009-04-09 | — | — | US | disclosed |
| US-20080269265-A1 | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas | MILLER SCOTT | 2008-10-30 | — | — | US | disclosed |
| EP-1616865-A1 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | Bayer Pharmaceuticals Corporation (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1042305-B1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER PHARMACEUTICALS CORP (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1049664-B1 | INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS | BAYER PHARMACEUTICALS CORP (US) | 2005-03-16 | — | — | EP | disclosed |
| EP-1449834-A2 | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas | Bayer Corporation (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20040102636-A1 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | BAYER CORPORATION | 2004-05-27 | — | — | US | disclosed |
| EP-1042305-A4 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER AG (US) | 2003-05-14 | — | — | EP | disclosed |
| CN-1283180-A | Inhibition of raf kinase using symmerical and unsymmerical substituted diphenyl ureas | BAYER AG (US) | 2001-02-07 | — | — | CN | disclosed |
| EP-1049664-A1 | INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS | Bayer Corporation (US) | 2000-11-08 | — | — | EP | disclosed |
| EP-1042305-A1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032436-A1 | INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032463-A1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093526-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | MAP2K2, MAPK1, MAP2K1 | HTR3E 3625/4885HTR3B 2612/4885HTR3A 2937/4885 |
| US-20040102636-A1 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | MAP2K2, MAPK1, MAP2K1 | HTR3E 3625/4885HTR3B 2612/4885HTR3A 2937/4885 |
| US-20120270878-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | MAP2K2, MAPK1, MAP2K1 | HTR3E 3625/4885HTR3B 2612/4885HTR3A 2937/4885 |
| US-20080269265-A1 | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas | BRAF, RAF1, MAP2K2 | HTR3E 4016/4885HTR3B 3856/4885HTR3A 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.